18F-FDG PET/CT in Patients with Nodular Pulmonary Amyloidosis: Case Report and Literature Review

Xiao-Qing Quan, Tie-Jun Yin, Cun-Tai Zhang, Jian Liu, Li-Fen Qiao, Chang-Shu Ke

Departments of *Geriatrics and bPathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Key Words
Amyloidosis · Pulmonary nodules · Lung cancer · 18F-FDG PET/CT

Abstract
A 62-year-old woman was found to have multiple bilateral pulmonary nodules showing different 18F-fluorodeoxyglucose (FDG) uptakes on positron-emission tomography/computed tomography (PET/CT). Only the largest nodule in the left lower lobe showed an increased 18F-FDG uptake on PET/CT. Three nodules were surgically resected from different lobes of the left lung. Two lobes were benign and showed amyloid deposition. The largest nodule in the left lower lobe showed adenocarcinoma and a heavy amyloid deposition. Pulmonary amyloidosis should be added to the differential diagnosis for cases with multiple pulmonary nodules that show different 18F-FDG uptakes on PET/CT. To the best of our knowledge, this is the second reported case of a lung nodule consisting of adenocarcinoma and amyloid deposition.

Introduction
Amyloidosis is a rare disorder in which insoluble fibrillar proteins are deposited in extracellular tissue [1]. Pulmonary involvement of amyloids may be localized or systemic, primary or secondary, hereditary or acquired [2]. Nodular pulmonary amyloidosis may manifest as single or multiple nodules, which are able to calcify or cavitate. It is usually misconstrued as primary lung carcinoma or metastatic tumor.

Positron-emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) is used to evaluate patients with possible cancers [3]. In the case
of pulmonary nodules, 18F-FDG PET has been demonstrated to have a high sensitivity and specificity for malignancy [4, 5]. In the present study, we report an unusual case of multiple pulmonary amyloid nodules in a patient with different 18F-FDG uptakes on PET/CT. We also conducted a review of the literature in PubMed, Embase and the ISI Web of Science looking for cases with histologically proven pulmonary amyloidosis who had undergone 18F-FDG PET/CT.

Case Report

A 62-year-old nonsmoking female presented with a 2-month history of cough with white phlegm and occasionally blood-tinged sputum. The patient did not have any other significant medical condition. She denied having any other symptoms, including chest pain, dyspnea, weight loss, fevers, chills, and night sweats. The findings of her physical examination were unremarkable.

The tumor marker NSE was mildly elevated to 17.63 μg/l (normal range 0–16.30). The other tumor markers, including CYFRA19, CEA and SCC, were within normal limits. The complete blood count, serum electrolytes, renal and liver function, and comprehensive metabolic profile findings were normal. Sputum smears and cultures were negative for acid-fast bacilli, fungi or other microorganisms. A pulmonary function test indicated increased airway resistance (2.05 cm H2O/l/s, 139% of predicted). An arterial blood gas analysis obtained while breathing room air revealed a PO2 of 92.6 mm Hg, a PCO2 of 45.5 mm Hg and a pH of 7.407. The electrocardiogram was normal and the echocardiogram revealed normal cardiac function. No echocardiographic signs of restrictive cardiomyopathy or cardiac amyloidosis were found.

High-resolution CT of the chest revealed multiple bilateral pulmonary nodules varying in size up to 3.5 cm, with no evidence of lymphadenopathy (fig. 1). The largest nodule measuring 3.5 × 2.5 cm was noticed in the posterior segment of the left lower lobe (fig. 1b). The mass and a few nodules showed focal, punctate calcifications. Calcification in the nodules was apparent in the mediastinal windows (fig. 1, right). Mediastinal lymphadenopathy was not present. The multiple lung nodules were suspicious of metastatic lesions from a hidden malignancy. To rule out a malignancy of the nodules, the patient underwent an 18F-FDG PET/CT scan (fig. 2). The PET/CT scan indicated an intense 18F-FDG activity in the left lower lobe (standard uptake value = 6.1), corresponding to the largest pulmonary nodule on the CT image. The degree of activity was highly suspicious of malignancy. The rest of the nodules in the lung fields did not show any uptake on the PET/CT scan. There were no metastases to other organs or bone lesions anywhere.

The patient underwent open lung biopsy to investigate the possibility of malignancy. Surgical exploration revealed widespread palpable nodules present on the surface of the left lung. Two small nodules from the apical and anterior segment of the left upper lobe, and the lingular segment of the left lower lobe, were wedged out and sent for frozen section procedure. The histopathologic findings of the two nodules were benign (fig. 3a). Then, the largest mass in the posterior segment of the left lower lobe was wedged out.

Histologically, all the resected nodules contained massive deposition of homogenous eosinophilic amorphous material with focal calcification. The eosinophilic material stained positive with Congo red (fig. 3c) and showed apple-green birefringence under polarizing microscopy, features pathognomonic of amyloidosis (fig. 3d). In addition to the amyloid material, minimally invasive adenocarcinoma (mainly) and a papillary predominant (focally) growth pattern were also found in the largest mass from the left lower lobe which showed...
an increased $^{18}$F-FDG uptake on PET/CT (fig. 3b). The postoperative pathological diagnosis was moderately differentiated adenocarcinoma of the lung (p-T1b,Nx,Mx, stage IA).

Afterwards, the patient was investigated for evidence of myeloma or plasma cell dyscrasias. All subsequent investigations including serum and urine protein electrophoresis and immunofixation, bone marrow biopsy and immunohistochemistry were normal. Until now, the patient has been followed up regularly with serial CT scans for 9 months. Her condition has remained unchanged, without significant clinical, physiological or radiological deterioration or evidence of systemic amyloidosis or recurrence of the adenocarcinoma.

**Literature Search**

We searched for previous cases of patients with histologically proven pulmonary amyloidosis who had undergone $^{18}$F-FDG PET/CT in the following databases: PubMed, EmBase and the ISI Web of Science. The search was limited, including the period from the year 2000 to October 2014, and to human studies and English-language publications. In the PubMed database, the search words were ‘amyloidosis’, ‘pulmonary’, ‘lung’, ‘PET/CT’, and ‘$^{18}$F-FDG’. Corresponding words were used in the EmBase database and the ISI Web of Science.

**Results of Different Publications**

We identified 19 articles [6–24] describing pulmonary amyloidosis and PET/CT scan in Medline, EmBase and the ISI Web of Science. Data on the clinical presentation, histopathological and imaging findings of 41 patients (including our case) are summarized in table 1 (PET positive) and table 2 (PET negative). There were 16 male and 23 female cases, while the age and gender were not indicated in 2 cases [9, 12]. Ages ranged from 32 to 85 years and, consistent with previous findings [17, 18, 24], the average age of the patients was in the sixth decade (64 years).

Radiologically, the nodular parenchymal pattern appeared as solitary (36%) or multinodular (64%) infiltrates in any lobe. Nodules ranged in diameter from satellite nodularity to 5.5 cm. Thirty-three patients had a positive $^{18}$F-FDG uptake on PET (table 1), whereas the maximum standard uptake value ranged from 1.2 to 15 (with a mean of 4.7, $n = 21$), and in 71% of cases, it was >2.5. Histopathologically, pulmonary involvement in amyloidosis can be associated with mucosa-associated lymphoid tissue lymphoma, plasma cells, giant cells, and other immunoreactive cells (macrophages, monocytes and lymphocytes).

**Discussion**

Amyloidosis is a group of disorders characterized by extracellular deposition of proteins in a β-pleated sheet fibrillar form. The most common presentations are nephrotic syndrome, idiopathic peripheral neuropathy, cardiomyopathy, and unexplained hepatomegaly [1]. Pulmonary involvement rarely causes symptoms unless gas exchange in alveolar structures is severely affected by amyloid deposits [2, 18, 24]. Histologically, amyloid deposits are identified on the basis of eosinophilic amorphous deposits which take up Congo red stain and typically exhibit apple-green birefringence when examined under polarized light [1, 7, 22, 24, 25].
Pulmonary nodules are seen in various pulmonary diseases, including tumor, tuberculosis and infection, but amyloidosis is infrequently considered as a candidate in the differential diagnosis of such lesions. The incidence of pulmonary amyloidosis is unclear because many cases are diagnosed incidentally during open lung biopsy or at autopsy. Quaia et al. [12] reported 76 patients with pulmonary tumor(s) suspected for malignancy between 2004 and 2006, and only 1 case was identified with amyloidosis.

For pulmonary amyloidosis, there are three types of location: parenchymal nodules (nodular parenchymal form), diffuse interstitial deposits (diffuse alveolar septal form) or submucosal deposits in the airways (tracheobronchial form) [2]. Calcification is common [15, 19, 20, 23], and a chest CT scan may show calcified deposits in over one third of patients with pulmonary amyloidosis [26]. In this study, the patient presented with multiple amyloid nodules with partial calcification in both lung fields on CT scan (fig. 1).

Nodular pulmonary amyloidosis is characterized by single or multiple parenchymal nodules or masses. The size of the nodules varies from a few millimeters to several centimeters. It is usually a silent disease and found incidentally on chest radiographs in asymptomatic, older individuals [17–19, 24, 25]. It may show a slow progression of increased size or number of nodules but not always reveals a restrictive pattern of lung function or impairment of gas exchange. The natural history of nodular pulmonary amyloidosis is associated with a relatively benign prognosis [2, 18, 19, 21, 25].

Because of its nodular appearance, nodular pulmonary amyloidosis is usually misconstrued as neoplasm. The differential diagnoses of multiple nodules include a broad spectrum of etiologies: infections, pneumoconiosis, tumor, sarcoidosis, rheumatoid arthritis, and other uncommon illnesses such as amyloidosis or pulmonary alveolar microlithiasis [2, 27].

PET/CT with 18F-FDG is used to identify focal areas of increased cellular metabolism [3–5]. 18F-FDG is an excellent tracer for identifying malignant lesions because of the high glucose metabolism observed in cancer cells. 18F-FDG PET is widely accepted as an important diagnostic tool in identifying potentially malignant lesions. 18F-FDG PET has a high sensitivity and specificity for the characterization of pulmonary nodules [5]. As with all diagnostic modalities, 18F-FDG PET gives false-positive [6–24] and false-negative [28–30] results. A number of metabolically active nonmalignant diseases, such as histoplasmosis, sarcoidosis, tuberculosis and aspergillosis, can result in increased 18F-FDG accumulation [3, 4]. On the other hand, tumors with low glycolytic activity such as carcinoid, localized bronchoalveolar carcinomas and small-sized tumors have revealed false-negative findings on a PET scan [28–30].

Several case reports mention patients with nodular pulmonary amyloidosis who underwent 18F-FDG PET/CT, most of them showing an increased FDG uptake (table 1), but no FDG uptake has also been mentioned (table 2). A recently published study by Glaudemans et al. [22] evaluated the role of 18F-FDG PET/CT in a group of patients with both systemic and localized amyloidosis; 18F-FDG uptake was seen in all patients with localized amyloidosis, but none was seen in all patients with systemic amyloidosis. The giant cells in localized amyloidosis may participate in the transformation of the soluble full-length light chains into insoluble fibrils [31]. The high amounts of serum amyloid P make the amyloid deposits unavailable for inflammatory phagocytic cells in systemic amyloidosis [32]. Two studies reported by Baqir et al. [20, 24] showed that mucosa-associated lymphoid tissue lymphoma was associated with pulmonary amyloid and 18F-FDG uptake, which might be due to plasma cell differentiation [33].

One case report by Miyazaki et al. [34] demonstrated the association of pulmonary amyloidosis with adenocarcinoma, but without manifestation by PET scan. In the current case, our patient had a cough of 2 months’ duration with no other symptoms. Being a
nonsmoker as well as the normal physical examination and negative routine workup results suggested a nonmalignant condition. However, due to the multiple bilateral pulmonary nodules found on chest CT and the need to exclude a neoplastic process, a PET/CT scan was initially performed. Intense focal $^{18}$F-FDG uptake of the largest nodule in the left lower lobe on the PET/CT scan indicated the possibility of malignancy. However, other nodules did not show an increased $^{18}$F-FDG uptake on PET/CT imaging and were thought to be benign. Later, an open-lung biopsy was performed. Although histopathologic findings of two nodules without increased $^{18}$F-FDG uptake suggested a benign lesion, a subsequent biopsy of the nodule with increased $^{18}$F-FDG uptake was still clinically required, which was later shown to be composed of adenocarcinoma and amyloid deposition. The nodules with a normal $^{18}$F-FDG uptake on PET/CT showed amyloid deposition. Thus, for multiple pulmonary nodules, the differential diagnosis should include malignant neoplasm, and histological confirmation is mandatory. Our study emphasizes the importance of screening for multiple pulmonary amyloid nodules with PET/CT in the case of suspected malignancy before a biopsy is undertaken.

A nodular pattern of amyloid deposition surrounding the adenocarcinoma in the lung is occasionally seen [34]. Little is known about the association between amyloidosis and the neoplastic condition. Intra- and extracellular amyloid deposition may contribute to the pathogenesis of the neoplastic condition [35]. Carcinoma-associated antigens might induce the deposition of the amyloidogenic immunoglobulin light chain and nodular lesions [36]. Considering that the lung cancer in our patient was present in only one of the multiple pulmonary amyloidosis nodules, amyloid deposition has probably developed before the neoplastic condition.

In conclusion, our case of pulmonary amyloidosis presenting with multiple nodules showed that PET/CT can be useful in disease management and decision-making before a biopsy is undertaken. Pulmonary amyloidosis needs to be added to the differential diagnosis when multiple pulmonary nodules show different $^{18}$F-FDG uptakes on PET/CT.

Acknowledgement

This study was supported by a grant from the National Natural Science Foundation of China (81400255).

Disclosure Statement

The authors declare that they have no conflicts of interest.

References

1. Pinney JH, Hawkins PN: Amyloidosis. Ann Clin Biochem 2012;49:229–241.
2. Lachmann HJ, Hawkins PN: Amyloidosis and the lung. Chron Respir Dis 2006;3:203–214.
3. Kwee TC, Basu S, Cheng G, Alavi A: FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging 2010;37:635–644.
4. Yamauchi M, Shinozaki K, Doi M, Nitta T, Nishisaka T: A case of gingival metastasis from rectal cancer in which immunohistochemistry and PET-CT were useful for the diagnostic procedure. Case Rep Oncol 2014;7:246–251.
5. Jeong SY, Lee KS, Shin KM, et al: Efficacy of PET/CT in the characterization of solid or partly solid solitary pulmonary nodules. Lung Cancer 2008;61:186–194.
Quan et al. 18F-FDG PET/CT in Patients with Nodular Pulmonary Amyloidosis: Case Report and Literature Review

Kung J, Zhuang H, Yu JQ, Duarte PS, Alavi A: Intense fluorodeoxyglucose activity in pulmonary amyloid lesions on positron emission tomography. Clin Nucl Med 2003;28:975–976.

Ollenhager GP, Knight S, Tauro AJ: False-positive FDG positron emission tomography in pulmonary amyloidosis. Clin Nucl Med 2004;29:657–658.

Pusatlaszski M, Kamei EM, Artemisia S, Genevay M, McKee T: Nodular pseudotumoral pulmonary amyloidosis mimicking pulmonary carcinoma. Thorax 2005;60:440.

Grustein A, Shriti D, Sapir EE, Cohen M, Kramer MR: Pulmonary amyloidosis: detection with PET-CT. Clin Nucl Med 2005;30:420–421.

Currie GP, Rosciter C, Dempsey OJ, Legge JS: Pulmonary amyloid and PET scanning. Respir Med 2005;99:1463–1464.

Yadav S, Sharma S, Gillilan I: Unusual positron emission tomography findings in pulmonary amyloidosis: a case report. J Cardiothorac Surg 2006;1:32.

Quaia E, Tona G, Gelain F, et al.: Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection. Acta Radiol 2008;49:995–1004.

Fukatsu H, Miyoshi H, Ishiki K: Spontaneous resolution of multiple nodular pulmonary AA amyloidosis. Intern Med 2010;49:2303–2307.

Tan H, Guan Y, Zhao J, Lin X: Findings of pulmonary amyloidosis on dual phase FDG PET/CT imaging. Clin Nucl Med 2010;35:206–207.

Seo JH, Lee SW, Ahn BC, Lee J: Pulmonary amyloidosis mimicking multiple metastatic lesions on F-18 FDG PET/CT. Lung Cancer 2010;67:376–379.

Sousan M, Ouvrier MJ, Pop G, Galas JL, Neuman A, Weinmann P: Tracheobronchial FDG uptake in primary amyloidosis detected by PET/CT. Clin Nucl Med 2011;36:723–724.

Melinian A, Jaccard A, Sousan M, et al.: 18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review. Amyloid 2012;19:94–98.

Zhang LN, Xue XY, Wang N, Wang JX: Mimicking pulmonary multiple metastatic tumors: a case of primary nodular parenchymal pulmonary amyloidosis with review of the literature. Oncol Lett 2012;4:1366–1370.

Khan AM, Manzoor K, Khan V, Mahadevia P, Berman A: Detection of nodular pulmonary amyloid by PET positive scan – deception for lung cancer. Rev Port Pneumol 2012;18:299–303.

Baqr M, Kluka EM, Aubry MC, et al.: Amyloid-associated cystic lung disease in primary Sjögren’s syndrome. Respir Med 2013;107:661–662.

Xu L, Frazier A, Burke A: Isolated pulmonary amyloidomas: report of 3 cases with histologic and imaging findings. Pathol Res Pract 2013;209:62–66.

Glaudemans AW, Slart RH, Noordzij W, Dierckx RA, Hazenberg BP: Utility of 18F-FDG PET/CT in patients with systemic and localized amyloidosis. Eur J Nucl Med Mol Imaging 2013;40:1095–1101.

Mulherje A, Dhill VS, Sharma P, et al.: Pulmonary amyloidosis in a patient with Langerhan cell histiocytosis: diagnostic dilemma on 18F-FDG PET/CT. Clin Nucl Med 2014;39:e263–e264.

Baqr M, Lowe V, Yi ES, Ryu JH: 18F-FDG PET scanning in pulmonary amyloidosis. J Nucl Med 2014;55:565–568.

Ozer Simsek Z, Oymak FS, Tutar N, Canoiz O, Demir R: A rare case of diffuse parenchymal lung disease together with granulomatous reaction: pulmonary amyloidosis. Case Rep Pulmonol 2013:2013:837190.

Urban BA, Fishman EK, Goldman SM, et al.: CT evaluation of amyloidosis: spectrum of disease. Radiographics 1993;13:1295–1308.

Kumar R, Saleh A, Amin B, Raoof S: A 73-year-old woman with mild shortness of breath and multiple central calcified pulmonary nodules. Chest 2008;134:460–464.

Gould MK, Maclean CC, Kuschnier WG, Rydzak CE, Owens DK: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914–924.

Veronesi G, Bellomi M, Veronesi U, et al.: Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. Ann Thorac Surg 2007;84:959–965, discussion 965–966.

Williams A, Gutzeit A, Germer M, Pless M: PET-negative gastrointestinal stromal tumors. Case Rep Oncol 2013;6:508–513.

Westernmark P: Localized AL amyloidosis: a suicidal neoplasm? Ups J Med Sci 2012;117:244–250.

Bodin K, Ellmerich S, Kahau MC, et al.: Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468:93–97.

Hoffmann M, Wohrer S, Becherer A, et al.: 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol 2006;17:1761–1765.

Miyazaki D, Yazaki M, Ishii W, et al.: A rare lung nodule consisting of adenocarcinoma and amyloid deposition in a patient with primary systemic AL amyloidosis. Intern Med 2011;50:243–246.

Melato M, Manconi R, Falconieri G: Amyloidosis and lung cancer. A morphological and histochemical study. Morphol Embryol (Bucur) 1981;27:137–142.

Van Nostrand WE, Melchor JP, Ruffini L: Pathologic amyloid beta-protein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. J Neurochem 1998;70:216–223.
Table 1. 18F-FDG PET-positive cases with nodular pulmonary amyloidosis described in the literature

| First author/year | Age, years / gender | Number of nodules | Maximum dimension, cm | Location of nodules | SUV<sub>max</sub> | Histological findings around amyloid deposits |
|-------------------|---------------------|-------------------|-----------------------|---------------------|----------------|---------------------------------------------|
| Kung [6], 2003    | 68 / F              | single            | 3.0                   | left upper lobe     | 6.8            | Mononuclear inflammatory cells              |
| Olffenberger [7], 2004 | 85 / M            | single            | 5.1                   | right upper lobe    | 2.4            | Mononuclear inflammatory cells              |
| Pusztaaszeri [8], 2005 | 72 / F            | single            | 2.4                   | left lung           | 2.4            | -                                           |
| Grubstein [9], 2005 | 59 / M             | single            | 1.0                   | left lung           | 2.4            | -                                           |
| Currie [10], 2005 | 73 / F             | single            | 2.4                   | right middle lobe   | 2.4            | -                                           |
| Yadav [11], 2006  | 55 / M             | multiple          | 2.5                   | bilateral           | 2.4            | -                                           |
| Quaia [12], 2008  | 70 / M             | multiple          | 1.0                   | right lung          | 1.0            | -                                           |
| Fukatsu [13], 2010 | 62 / M             | multiple          | 1.0                   | left lung           | 1.0            | -                                           |
| Tan [14], 2010    | 54 / F             | multiple          | 1.0                   | right lung          | 1.0            | -                                           |
| Seo [15], 2010    | 85 / M             | multiple          | 1.0                   | left lung           | 1.0            | -                                           |
| Soussan [16], 2011 | 59 / M             | multiple          | 1.0                   | right lung          | 1.0            | -                                           |
| Mekinian [17], 2012 | 62 / M          | multiple          | 1.0                   | left lung           | 1.0            | -                                           |
| Zhang [18], 2012  | 44 / M             | multiple          | 1.0                   | left lung           | 1.0            | A few lymphocytes                           |
| Khan [19], 2012   | 68 / M             | single            | 2.0                   | right upper lobe    | 2.0            | -                                           |
| Baqir [20], 2013  | 53 / F             | multiple          | 1.0                   | right upper lobe    | 2.0            | MALT lymphoma                               |
| Xu [21], 2013     | 62 / M             | multiple          | 2.0                   | bilateral           | 1.9            | Scattered plasma cells                      |
|                  | 75 / M             | multiple          | 3.0                   | bilateral           | 4.0            | Macrophage giant cells, plasma cells        |
| Glaudemans [22], 2013 | 56 / F      | multiple          | 3.0                   | right lung          | 3.0            | -                                           |
|                  | 81 / F             | single            | 3.0                   | right lung          | 3.0            | -                                           |
|                  | 62 / M             | single            | 3.0                   | right lung          | 3.0            | -                                           |
|                  | 72 / F             | multiple          | 3.0                   | right lung          | 3.0            | -                                           |
| Mukherjee [23], 2014 | 48 / M            | single            | 5.5                   | left upper lobe     | 4.4            | -                                           |
| Baqir [24], 2014  | 64 / F             | multiple          | 5.5                   | left upper lobe     | 5.2            | MALT lymphoma                               |
|                  | 78 / F             | multiple          | 5.5                   | left upper lobe     | 6.7            | MALT lymphoma                               |
|                  | 67 / M             | multiple          | 5.5                   | left upper lobe     | 2.1            | -                                           |
|                  | 73 / F             | multiple          | 5.5                   | left upper lobe     | 5.7            | MALT lymphoma                               |
|                  | 69 / F             | multiple          | 5.5                   | left upper lobe     | 7.2            | Plasmacytoma                                |
|                  | 54 / F             | multiple          | 5.5                   | left upper lobe     | 3.2            | -                                           |
|                  | 75 / F             | multiple          | 5.5                   | left upper lobe     | 2.6            | -                                           |
|                  | 75 / M             | single            | 5.5                   | left upper lobe     | 3.1            | MALT lymphoma                               |
| Present case     | 62 / M             | multiple          | 2.5                   | bilateral           | 6.1            | Adenocarcinoma                              |

SUV<sub>max</sub> = Maximum standardized uptake value; F = female; M = male; MALT = mucosa-associated lymphoid tissue; – = not stated.
Table 2. \(^{18}\)F-FDG PET-negative cases with nodular pulmonary amyloidosis described in the literature

| First author/year | Age, years / gender | Number of nodules | Maximum dimension, cm | Location of nodules | Histological findings around amyloid deposits |
|-------------------|---------------------|-------------------|-----------------------|---------------------|---------------------------------------------|
| Grubstein [9], 2005 | -                   | -                 | -                     | -                   | -                                           |
| Mekinian [17], 2012 | 49 / F              | -                 | -                     | -                   | -                                           |
|                   | 66 / F              | -                 | -                     | -                   | -                                           |
| Baqir [20], 2013   | 74 / F              | multiple          | bilateral             | MALT lymphoma       |                                             |
|                   | 75 / F              | multiple          | bilateral             | -                   |                                             |
|                   | 32 / F              | multiple          | bilateral             | -                   |                                             |
|                   | 58 / F              | multiple          | bilateral             | -                   |                                             |
|                   | 39 / M              | multiple          | bilateral             | follicular bronchiolitis |                                             |

F = Female; M = male; MALT = mucosa-associated lymphoid tissue; - = not stated.

Fig. 1. a, b CT scans (lung window, left) showing variably sized multiple nodules of up to 3.5 cm in both lung fields. Focal punctate calcifications in the nodules are apparent in the mediastinal windows (right). The largest nodule is noticed in the posterior segment of the left lower lobe (b).
Fig. 2. a, b PET scans showing intense ¹⁸F-FDG activity (maximum standard uptake value = 6.1) corresponding to a nodule in the left lower lobe on CT scan. The rest of the lesions in the lung fields do not show any uptake on PET scan. There are no metastases to other organs or bone lesions anywhere (b).
**Fig. 3.** Histopathological findings of resected pulmonary nodules are shown. 

- **a** The frozen section procedure showed benign nodules.
- **b** The largest nodule in the left lower lobe consists of minimally invasive adenocarcinoma (mainly) and a papillary predominant growth pattern (focally) as well as massive interstitial deposition of homogenous eosinophilic amorphous material.
- **c** Congo red staining of the lung lesion. The amorphous eosinophilic material is colored pink or red with the use of the Congo red stain.
- **d** The eosinophilic material showed apple-green birefringence under polarizing microscopy when stained with Congo red, consistent with amyloidosis.